EGFR and colorectal carcinoma: The EGFR inhibitors cetuximab and panitumumab proved effective in RAS WT CRC (32, 33) and the BRAF inhibitor encorafenib demonstrated efficacy in the treatment of BRAF V600E mutant CRC (34).